Pacific Edge shares more than double on US healthcare news

Pacific Edge shares more than double on US healthcare news
Brent Melville
Pacific Edge shares more than doubled in value on confirmation of acceptance under a key US medical regulation for its Cxbladder cancer test. The shares jumped as high as 68 cents from 27 cents yesterday, and were recently at 55 cents, up 104 percent and valuing the company at $379.3 million. The successful standard of care rating from the US Centres for Medicare and Medicaid Services means Pacific Edge will be reimbursed at a rate of US$760 per test from July 1, 2020.  The CMS provides healthcare coverage for all US citizens over the...

More Listed Companies

How ‘shareholder value’ became a Wall Street mantra
Policy

How ‘shareholder value’ became a Wall Street mantra

Michael Jensen inspired the transformation of capitalism. Was he a hero or a villain?

Bloomberg 13 Apr 2024
How many boards should a director sit on?
Listed Companies

Simon Robertson: How many boards should a director sit on?

An attempt to judge the composition trends in NZX boards is challenging.

Simon Robertson 13 Apr 2024
Wellington council picks Precinct for major civic square project
Property

Wellington council picks Precinct for major civic square project

Firm will fund and build the new five-star green building.

Staff reporters 11 Apr 2024
Numbers and letters for investors
Markets

Simon Robertson: Numbers and letters for investors

A plea for standardised financial reporting from NZX-listed companies.

Simon Robertson 02 Mar 2024